Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > About us About us Crescendo Biologics is focused on novel T cell enhancing therapeutics in immuno-oncology Crescendo Biologics (Crescendo) is a clinical stage company, focused on transforming the lives of cancer patients through its pipeline of novel, T cell enhancing therapies. The lead programme, CB307, is a first in class PSMA x CD137 (4-1BB) bispecific molecule. Behind the lead programme there is a pipeline of other first or best in class CD137 (4-1BB) and other bispecifics for the treatment of cancers. T cell enhancing pipeline advantages: Enhanced safety via conditional activation of only tumour-specific T cells, localised in the tumour micro-environment Proliferation of tumour-specific T cells to drive a broad tumour cell killing Survival of tumour-specific T cells for a more durable anti-cancer effect (‘memory’ responses) Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® VH platform. Some of the key Humabody VH platform benefits include: Rapid discovery process Fully human VH domains (Humabodies) – no humanisation step is required Exceptional diversity and excellent hit rates Small size with ability to reach epitopes that monoclonal antibodies cannot Clearly differentiated tissue accumulation and tissue penetration compared to conventional monoclonal antibodies Robust chemical and physical stability Easily assembled into multi-specific formats (MultiBody®s), which can be formatted to access novel biology Tuneable half-life Multiple administration routes Excellent expression yields and established manufacturing processes Crescendo has a global, strategic, multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M. It also licensed global rights to its first programme, for a target in inflammation, to Zai Lab in 2018 and entered into a clinical development partnership with Cancer Research UK for a programme in immuno-oncology in 2020. Located in Cambridge, UK, Crescendo is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group plc, Takeda and Quan Capital. Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design